TLR9 Agonist SD-101

DRUG4 trials

Conditions

Advanced Malignant Solid NeoplasmB-Cell Non-Hodgkin LymphomaExtracranial Solid NeoplasmGrade 1 Follicular LymphomaGrade 2 Follicular LymphomaGrade 3a Follicular LymphomaLymphoplasmacytic LymphomaMantle Cell Lymphoma

Phase 1

TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma

CompletedNCT02927964

Robert LowskyGrade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma +4

Start: 2016-11-07End: 2023-05-18Updated: 2024-10-16

TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin Lymphomas

CompletedNCT03410901

Ronald LevyB-Cell Non-Hodgkin Lymphoma, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma +5

Start: 2018-04-09End: 2024-10-10Updated: 2024-12-11

SD-101 and BMS-986178 in Treating Patients With Advanced or Metastatic Solid Malignancies

CompletedNCT03831295

Ronald LevyAdvanced Malignant Solid Neoplasm, Extracranial Solid Neoplasm, Metastatic Malignant Solid Neoplasm

Start: 2019-03-13End: 2021-10-04Updated: 2023-11-22

SD-101, Nivolumab, and Radiation Therapy in Treating Patients With Chemotherapy-Refractory Metastatic Pancreatic Cancer

CompletedNCT04050085

University of California, DavisMetastatic Pancreatic Adenocarcinoma, Refractory Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8

Start: 2019-08-15End: 2022-05-14Updated: 2023-08-01

Blood Advances2023-11-084 citations

Loss of the OX40 Target in Lymphoma Patients after Combining an Anti-OX40 Agonist Antibody with in Situ Vaccination

Blood2023-11-02

Activating Immune Effectors and Dampening Immune Suppressors Generates Successful Therapeutic Cancer Vaccination in Patients with Lymphoma

Blood2022-11-151 citations

Prevalence of Acquired N-Glycosylation Sites at the Single Cell Level in Follicular Lymphoma

Blood2022-11-15

Therapeutic and Immunologic Responses Elicited By in Situ Vaccination with CpG, Ibrutinib, and Low-Dose Radiation

Blood2021-11-05

In Situ Vaccination Induces Changes in Follicular Lymphoma Tumor Cells That Correlate with Abscopal Clinical Regressions

Blood2021-11-05

Single Cell Analysis of Serial Lymphoma Biopsies Reveals Dynamic Immune Modulation and Predictors of Response in Patients Undergoing in Situ Vaccination

Blood2020-11-051 citations

Intratumoral CpG, Local Radiation, and Oral Ibrutinib Combine to Produce Effective in Situ Vaccination in Patients with Low-Grade B-Cell Lymphoma

Blood2020-11-044 citations

A pilot study of intratumoral SD-101 (toll-like receptor 9 agonist), nivolumab, and radiotherapy for treatment of chemotherapy-refractory metastatic pancreatic adenocarcinoma.

Journal of Clinical Oncology2020-02-016 citations

Site to Site Comparison of Follicular Lymphoma Biopsies By Single Cell RNA Sequencing

Blood2019-11-135 citations

A Phase I/II Trial of Intratumoral CpG, Local Low-Dose Radiation, and Oral Ibrutinib in Patients with Low-Grade B-Cell Lymphoma

Blood2019-11-132 citations

Dynamic Immune Modulation Seen By Single Cell RNA-Sequencing of Serial Lymphoma Biopsies in Patients Undergoing in Situ Vaccination

Blood2019-11-13

Abstract CT133: Interim results of a Phase I/II trial of intratumoral CpG, local low-dose radiation, and oral ibrutinib in patients with low-grade B-cell lymphoma

Clinical Trials2019-07-01

Abstract 4045: Single cell RNA sequencing of serial tumor and blood biopsies from lymphoma patients undergoing in situ vaccination

Cancer Research2019-07-01

Abstract CT133: Interim results of a Phase I/II trial of intratumoral CpG, local low-dose radiation, and oral ibrutinib in patients with low-grade B-cell lymphoma

Cancer Research2019-07-01

Abstract 4045: Single cell RNA sequencing of serial tumor and blood biopsies from lymphoma patients undergoingin situvaccination

Clinical Research (Excluding Clinical Trials)2019-07-01

A PHASE I/II TRIAL OF IBRUTINIB, INTRATUMORAL CPG AND LOCAL RADIATION IN PATIENTS WITH LOW‐GRADE B‐CELL LYMPHOMA: INTERIM CLINICAL AND CORRELATIVE RESULTS

Hematological Oncology2019-06-01

Immunotherapeutic effects of intratumoral nanoplexed poly I:C

Journal for ImmunoTherapy of Cancer2019-05-02125 citations

Intratumoral Injection of CpG-ODN Plus Systemic Ibrutinib Induces an Anti-Tumor Immune Response Affecting T Cell Subsets in the Microenvironment of Both Injected and Non-Injected Tumor Sites in Patients with Low-Grade Lymphoma

Blood2018-11-291 citations

Single Cell RNA Sequencing of Serial Tumor and Blood Biopsies from Lymphoma Patients on an in Situ Vaccination Clinical Trial

Blood2018-11-29

TLR9 Agonist SD-101

Sponsors

Conditions

Phase 1

Related Papers